Thera-SAbDab

VOBARILIZUMAB

>   Structural Summary
TherapeuticVobarilizumab
Target 1IL6R
Heavy Chain 1EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS
Light Chain 1na
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2ALB
Heavy Chain 2EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS
Light Chain 2na
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Metadata
FormatBispecific Single Domains (VH-VH')
Isotypena
Highest Clinical Trial (Jan '20)Phase-II
Estimated Status (Jan '20)Active
Recorded Developmental TechnologyNanobody Technology
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedAblynx
Conditions Approvedna
Conditions ActiveRheumatoid arthritis, Systemic lupus erythematosus
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]